natgillin/translations-raw huggingface dataset:
The entecavir dosage was 0.5 mg daily in the pivotal studies (mean exposure 85 weeks) and 1 mg daily in the rollover study (mean exposure 177 weeks), and 51 patients in the rollover study initially also received lamivudine (median duration 29 weeks). 
V ključnih študijah so bolniki prejemali entekavir v odmerku 0,5 mg na dan (srednji čas izpostavljenosti 85 tednov), v obnovljeni študiji pa 1 mg na dan (srednji čas izpostavljenosti
Entecavir Accord tablets are also used to treat chronic (long term) HBV infection in children and adolescents aged 2 years to less than 18 years. 
Entecavir Accord tablete uporabljamo tudi za zdravljenje kronične (dolgotrajne) okužbe s HBV
Therefore, therapy with entecavir should not be used for HIV/HBV co-infected patients who are not receiving HAART. 
Pri bolnikih s sočasno okužbo z virusoma HIV in HBV, ki se ne zdravijo po režimu HAART, se entekavir torej ne sme uporabljati.
At end of dosing, among patients who continued treatment beyond 52 weeks (median of 96 weeks), 81% of 243 entecavir-treated and 39% of 164 lamivudine-treated patients had HBV DNA < 300 copies/ml by PCR while ALT normalisation (≤ 1 times ULN) occurred in 79% of entecavirtreated and 68% of lamivudine-treated patients. 
81% od 243 z entekavirjem zdravljenih bolnikov in 39% od 164 z lamivudinom zdravljenih bolnikov imelo HBV DNA < 300 kopij/ml (s PCR), normalne vrednosti ALT (≤ 1 krat ULN) pa 79% z entekavirjem zdravljenih in 68% z lamivudinom zdravljenih bolnikov.
Two-year carcinogenicity studies: in male mice, increases in the incidences of lung tumours were observed at exposures ≥ 4 and ≥ 2 times that in humans at 0.5 mg and 1 mg respectively. 
Dvoletne študije kancerogenosti: pri mišjih samcih so opazili večjo pojavnost pljučnih tumorjev pri izpostavljenosti ≥ 4-krat od izpostavljenosti človeka pri odmerku 0,5 mg in ≥ 2-kratni izpostavljenosti človeka pri odmerku 1 mg. Pred pojavom tumorja so zasledili proliferacijo pnevmocitov, česar pa pri podganah, psih ali opicah niso opazili, kar kaže, da je ključni dogodek pri razvoju pljučnega tumorja, ki so ga opazili pri miših, lahko vrstno specifičen.
Entecavir Accord 1 mg film-coated tablets entecavir 
Entecavir Accord 1 mg filmsko obložene tablete entekavir
b NC=F (noncompleter=failure), meaning treatment discontinuations before the analysis week, including reasons such as death, lack of efficacy, adverse event, noncompliance/loss-to-follow-up, are counted as failures (e.g., HBV DNA ≥ 300 copies/ml) c NC=M (noncompleters=missing) dDefined as decrease or no change from baseline in CTP score. 
Vzroki za predčasno prekinitev zdravljenja so lahko smrt, pomanjkanje učinkovitosti, neželeni učinki, nesodelovanje bolnika, onemogočeno spremljanje bolnika ipd. c NC=M (bolnik, pri katerem študija ni bila dokončana=manjkajoči podatek).
*p<0.05 
*p vrednost v primerjavi z lamivudinom < 0,05
Exacerbations of hepatitis: spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT. After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline (see section 4.8). 
Pri nekaterih bolnikih se po uvedbi protivirusnega zdravljenja vrednosti serumske ALT lahko povišajo, medtem ko se vrednosti serumske HBV DNA zmanjšajo (glejte poglavje 4.8).
0.3 mg once daily* OR 0.5 mg every 48 hours 
0,5 mg vsakih 48 ur
For patients with baseline Ishak fibrosis score ≥ 2, 25/43 (58%) 
≥ 2-točki ugotovili pri 25/43 bolnikov (58%).
Entecavir Accord 1 mg film-coated tablets Bottle packs: 
Entecavir Accord 1 mg filmsko obložene tablete Pakiranje v plastenkah:
Entecavir Accord 0.5 mg film-coated tablets 
Entecavir Accord 0,5 mg filmsko obložene tablete
Entecavir Accord 0.5 mg film-coated tablets Bottle packs: 
Entecavir Accord 0,5 mg filmsko obložene tablete Pakiranje v plastenkah:
Patients should be monitored closely for adverse reactions when entecavir is coadministered with such medicinal products. 
Bolnike, ki se sočasno zdravijo z entekavirjem in omenjenimi zdravili, je treba skrbno nadzirati glede pojava neželenih učinkov.
Entecavir Accord 0.5 mg film-coated tablets: White to off white, triangle shaped, biconvex filmcoated tablets debossed with ‘J' on one side and ‘110' on other side. 
Entecavir Accord 0,5 mg filmsko obložene tablete: bele do umazano bele barve, bikonveksne in trikotne oblike.
Elimination: entecavir is predominantly eliminated by the kidney with urinary recovery of unchanged drug at steady-state of about 75% of the dose. 
V stanju dinamičnega ravnovesja se približno 75% odmerka izloči v nespremenjeni obliki.
Pre-existing lamivudine-resistant HBV is associated with an increased risk for subsequent entecavir resistance regardless of the degree of liver disease; in patients with decompensated liver disease, virologic breakthrough may be associated with serious clinical complications of the underlying liver disease. 
Že obstoječa odpornost virusa HBV proti lamivudinu je povezana z večjim tveganjem za kasnejši razvoj odpornosti proti entekavirju, ne glede na stopnjo bolezni jeter.
These trials provide experience in 195 HBeAg-positive nucleosidetreatment-naïve subjects treated with entecavir for a median duration of 99 weeks. 
195 HBeAg pozitivnih bolnikih, ki se predhodno še niso zdravili z nukleozidi.
Mild 
Normalen
Proportion undetectable (<300 copies/ml)b 49%* Mean change from baseline (log10 copies/ml) 
Delež nedokazljivih (<300 kopij/ml)b
An oral solution may be available for patients with body weight less than 32.6 kg. 
Pri bolnikih s telesno maso, manjšo od 32,6 kg, je treba uporabljati peroralno raztopino.
In studies in nucleoside-naive patients, 6% of entecavir-treated patients and 10% of lamivudine-treated patients experienced ALT elevations (> 10 times ULN and > 2 times reference [minimum of baseline or last end-of-dosing measurement]) during post-treatment follow-up. 
študijah pri bolnikih, ki se še niso zdravili z nukleozidi, so se med spremljanjem po zdravljenju vrednosti ALT povečale (za > 10 krat od ULN in > 2 krat od referenčne vrednosti [najmanjše ob izhodišču ali zadnje, izmerjene ob prekinitvi zdravljenja]) pri 6% bolnikov, ki so se zdravili z entekavirjem in 10% bolnikov, ki so se zdravili z lamivudinom.
Each tablet contains entecavir monohydrate equivalent to 0.5 mg entecavir. 
Ena tableta vsebuje 0,5 mg entekavirja v obliki entekavir monohidrata.
Each tablet contains entecavir monohydrate equivalent to 1 mg entecavir. 
Ena tableta vsebuje 1 mg entekavirja v obliki entekavir monohidrata.
The time to onset of HCC or death (whichever occurred first) was comparable in the two treatment groups; on-study cumulative death rates were 23% (23/102) and 33% (29/89) for patients treated with entecavir and adefovir dipivoxil, respectively, and on-study cumulative rates of HCC were 12% (12/102) and 20% (18/89) for entecavir and adefovir dipivoxil, respectively. 
Pri bolnikih, ki so se zdravili z entekavirjem, je bil kumulativni delež smrtnih izidov med študijo 23-odstoten (23/102), pri bolnikih, ki so se zdravili z adefovirdipivoksilom pa 33-odstoten (29/89).
Method of administration Entecavir Accord should be taken orally. 
Zdravilo Entecavir Accord mora bolnik jemati peroralno.
Week 96 . 
177 tednov).
Talk to your doctor or pharmacist before taking Entecavir Accord if you have ever had problems with your kidneys, tell your doctor. 
Pred začetkom jemanja zdravila Entecavir Accord se posvetujte s svojim zdravnikom ali s farmacevtom.
Among entecavir-treated patients, on-treatment ALT elevations had a median time to onset of 4-5 weeks, generally resolved with continued treatment, and, in a majority of cases, were associated with a ≥ 2 log10/ml reduction in viral load that preceded or coincided with the ALT elevation. 
Pri bolnikih, ki so se zdravili z entekavirjem, so se poslabšanja med zdravljenjem pojavila v povprečju po 4 - 5 tednih zdravljenja in so običajno pri nadaljevanju zdravljenja izzvenela.
Liver transplant recipients: renal function should be carefully evaluated before and during entecavir therapy in liver transplant recipients receiving cyclosporine or tacrolimus (see section 5.2). 
Bolniki s presajenimi jetri: Pri bolnikih s presajenimi jetri, ki se zdravijo s ciklosporinom ali takrolimusom, je treba pred začetkom zdravljenja z entekavirjem skrbno oceniti delovanje ledvic.
Entecavir Accord 1 mg film-coated tablets: Pink, triangle shaped, biconvex film-coated tablets debossed with 'J' on one side and '111' on other side. 
Entecavir Accord 1 mg filmsko obložene tablete: rožnate barve, bikonveksne in trikotne oblike.
Mean serum HBV DNA by PCR was 7.83 log10 copies/ml and mean serum ALT was 100 U/l; 54% of patients were HBeAg positive, and 35% of patients had LVDr substitutions at baseline. 
Srednja vrednost HBV DNA (s PCR) v izhodišču je bila 7,83 log10 kopij/ml, srednja vrednost ALT v serumu pa 100 enot/l.
Entecavir Accord 0.5 mg film-coated tablets entecavir 
Entecavir Accord 0,5 mg filmsko obložene tablete entekavir
Serum ALT should be persistently elevated for at least 6 months prior to treatment of paediatric patients with compensated liver disease due to HBeAg positive chronic hepatitis B; and for at least 12 months in patients with HBeAg negative disease. 
Pri pediatričnih bolnikih s kompenzirano boleznijo jeter zaradi HBeAg pozitivnega kroničnega hepatitisa B mora biti serumska vrednost ALT pred uvedbo zdravljenja persistentno povečana vsaj
Package leaflet: Information for the user Entecavir Accord 0.5 mg film-coated tablets Entecavir Accord 1 mg film-coated tablets entecavir 
Navodilo za uporabo Entecavir Accord 0,5 mg filmsko obložene tablete Entecavir Accord 1 mg filmsko obložene tablete entekavir
Entecavir Accord can be used in people whose liver is damaged but still functions properly (compensated liver disease) and in people whose liver is damaged and does not function properly (decompensated liver disease). 
Zdravilo Entecavir Accord se lahko uporablja tako pri bolnikih z okvaro jeter, ki še delujejo normalno (kompenzirana bolezen jeter),
Laboratory test abnormalities: through week 48 among entecavir-treated patients with decompensated liver disease, none had ALT elevations both > 10 times ULN and > 2 times baseline, and 1% of patients had ALT elevations > 2 times baseline together with total bilirubin > 2 times ULN and > 2 times baseline. 
Odstopanja od normalnih vrednosti laboratorijskih preiskav: med 48-tedenskim zdravljenjem pri nobenem od bolnikov, ki so prejemali entekavir, niso poročali o zvišanju vrednosti ALT, ki bi bile več kot 10 krat večje od zgornje meje normalne vrednosti (ULN - Upper Limit of Normal) in sočasno več kot 2 krat večje od izhodiščnih vrednosti.
Among entecavir-treated nucleoside naive patients, post-treatment exacerbations had a median time to onset of 23-24 weeks, and most were reported in HBeAg negative patients (see section 4.8). 
Pri predhodno z nukleozidi nezdravljenih bolnikih, ki so se zdravili z entekavirjem, so se poslabšanja po zdravljenju pojavila v povprečju 23 - 24 tednov po prekinitvi zdravljenja.
0.15 mg once daily* OR 0.5 mg every 72 hours 
0,5 mg vsakih 72 ur
(see a. Summary of the safety profile and section 5.1) 
(glejte poglavje 5.1) pri odraslih:
Bottle pack: 
Pakiranje v plastenki:
Also, patients with decompensated liver disease may be at higher risk for lactic acidosis and for specific renal adverse events such as hepatorenal syndrome. 
(ne glede na vzrok), še posebej pri bolnikih, ki so po Child-Turcotte-Pugh-ovi (CTP) lestvici spadali v skupino C. Pri bolnikih z dekompenzirano boleznijo jeter je večje lahko tudi tveganje za pojav laktacidoze in specifičnih neželenih učinkov na ledvicah, na primer hepatorenalnega sindroma.
Always take the dose recommended by your doctor to ensure that your medicine is fully effective and to reduce the development of resistance to treatment. 
Da bi bila korist zdravila popolna, tveganje za pojav odpornosti na zdravljenje pa čim manjše, morate vedno jemati le odmerek, ki vam ga je predpisal zdravnik.
* for doses < 0.5 mg entecavir oral solution is recommended. 
0,5 mg vsakih 72 ur * za odmerke < 0,5 mg priporočamo uporabo peroralne raztopine entekavirja.
Reductions in HIV RNA have been reported in HIV/HBV co-infected patients receiving entecavir monotherapy without HAART. 
Pri bolnikih s sočasno okužbo z virusoma HIV in HBV, ki so se zdravili samo z entekavirjem, brez zdravljenja po režimu HAART, so poročali o zmanjšanju vrednosti HIV RNA.
Albumin levels < 2.5 g/dl occurred in 30% of patients, lipase levels > 3 times baseline in 10% and platelets < 50,000/mm3 in 20%. 
Pri 10% bolnikov so bile vrednosti lipaze > 3 krat večje od izhodiščnih vrednosti, število trombocitov pa je bilo pri 20% bolnikov < 50.000/mm3.
Subjects were randomized (2:1) to receive blinded treatment with entecavir 0.015 mg/kg up to 0.5 mg/day (N = 120) or placebo (N = 60). 
180 z nukleozidi predhodno še nezdravljenimi otroci in mladostniki, starimi od 2 do < 18 let, s HBeAg pozitivno kronično okužbo z virusom hepatitisa B, kompenzirano boleznijo jeter in povečano vrednostjo ALT. Bolnike so randomizirali (2:1) na slepo zdravljenje z entekavirjem v odmerku 0,015 mg/kg do največ 0,5 mg/dan (N = 120) ali placebo (N = 60).
At the time of the long-term biopsy, all patients had HBV DNA < 300 copies/ml and 49/57 (86%) had serum ALT ≤ 1 times ULN. 
Po dolgotrajnem zdravljenju so imeli vsi bolniki v času biopsije vrednost HBV DNA < 300 kopij/ml.
3 of the 10 patients experienced virologic breakthrough (≥ 1 log10 increase above nadir). 
Pri dveh od teh 3 bolnikov je prišlo do povečanja virusnega bremena (glejte preglednico).
The active substance is entecavir. 
Absorpcija: Absorpcija entekavirja je hitra.
Lamivudine-refractory patients (i.e. with evidence of viraemia while on lamivudine or the presence of lamivudine resistance [LVDr] mutations) (see sections 4.4 and 5.1): the recommended dose in adults is 1 mg once daily, which must be taken on an empty stomach (more than 2 hours before and more than 2 hours after a meal) (see section 5.2). 
Bolniki, neodzivni na lamivudin (to je z dokazano viremijo med zdravljenjem z lamivudinom ali prisotnostjo mutacij, povezanih z odpornostjo na lamivudin [LVDr]) (glejte poglavji 4.4 in 5.1):
For patients originally assigned to entecavir treatment, the reduction in HBV DNA at 48 weeks was -4.20 log10 copies/ml, ALT normalisation had occurred in 37% of patients with abnormal baseline ALT and none achieved HBeAg seroconversion. 
Pri bolnikih, ki so od začetka prejemali entekavir, so se vrednosti HBV DNA v 48. tednu zmanjšale za -4,20 log10 kopij/ml,
*p value vs lamivudine < 0.05 a patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score ≥ 2) b a primary endpoint. 
a bolniki z ovrednoteno histološko sliko v izhodišču (stopnja vnetja in nekroze po Knodell-u v izhodišču ≥ 2)
In clinical studies with lamivudine-refractory patients, 4% had ALT elevations > 3 times baseline, and < 1% had ALT elevations > 2 times baseline together with total bilirubin > 2 times ULN and > 2 times baseline. 
Pri 1% bolnikov so bile vrednosti ALT > 2 krat večje od izhodiščnih vrednosti in sočasno povečane tudi vrednosti skupnega bilirubina, ki so bile > 2 krat večje od zgornje meje normalne vrednosti in > 2 krat večje od izhodiščnih vrednosti.
- genotypic ETVrc with virologic breakthrough d 
- genotipsko ETVr c s d povečanjem virusnega bremena a
Invented name Strength Pharmaceutical Form 
Izmišljeno ime Jakost
Route of administration Packaging 
Način uporabe zdravila
Date of first authorisation: 11 January 2008 Date of latest renewal: 11 January 2013 
Datum prve odobritve: 11. januar 2008 Datum zadnjega podaljšanja: 11. januar 2013
Your doctor may therefore have to monitor the condition of your liver. 
Zdravnik bo zato morda moral spremljati stanje vaših jeter.
Relationship between concentration and effect 
Povezava med koncentracijo in učinkom
Difference (95 % CI) 
Razlika (95 % IZ)
Swirl the vial gently. 
Vialo nežno vrtite.
Elderly (≥65 years) 
Starejši (≥ 65 let)
Other side effects that have been reported are listed below. 
Ostali neželeni učinki o katerih so poročali so navedeni spodaj.
Pack sizes: 1 or 10 vials. 
Velikost pakiranja: 1 ali 10 vial.
The safety profile of aprepitant was evaluated in approximately 6,500 adults and 184 children and adolescents. 
Varnostni profil aprepitanta je bil ovrednoten pri približno 6.500 odraslih in 184 otrocih in mladostnikih.
**N: Number of adult patients included in the primary analysis of complete response. 
**N: Število odraslih bolnikov vključenih v primarno analizo popolnega odziva.
NR = Not Reported 
NP = ni poročano
What IVEMEND is and what it is used for 
Kaj je zdravilo IVEMEND in za kaj ga uporabljamo
From a microbiological point of view, the medicinal product should be used immediately. 
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj po pripravi.
Please talk to your doctor or pharmacist if you are taking any of the following medicines: 
Obvestite zdravnika ali farmacevta, če jemljete katero koli od naslednjih zdravil:
†Difference and confidence interval (CI) were calculated using the method proposed by Miettinen and Nurminen and adjusted for gender. 
†Razlika in interval zaupanja (IZ) sta bila izračunana z uporabo metode po Miettinenu in Nurminenu in sta bila prilagojena glede na spol.
In the event of overdose, fosaprepitant should be discontinued and general supportive treatment and monitoring should be provided. 
V primeru prevelikega odmerjanja je treba dajanje fosaprepitanta prekiniti in uvesti splošno podporno zdravljenje ter nadzor.
A summary of the primary and secondary endpoints is shown in Table 7. 
Povzetek primarnih in sekundarnih opazovanih dogodkov je prikazan v preglednici 7.
Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000), not known (cannot be estimated from the available data). 
Pogostnost je opredeljena kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
This effect was not considered clinically important. 
Ta učinek ni veljal za klinično pomembnega.
CYP3A4 interactions 
Interakcije s CYP3A4
The safety and efficacy of IVEMEND in infants below 6 months of age have not been established. 
Varnost in učinkovitost zdravila IVEMEND pri dojenčkih, mlajših od 6 mesecev, nista bili dokazani.
Complete response† Delayed phase‡ Complete response† Overall§ 
Popoln odziv† Zapoznela faza‡ Popoln odziv† Celotna faza§ Akutna faza§§
Occupancy of brain NK1 receptors, in this study, correlate well with aprepitant plasma concentrations. 
Zasedenost možganskih receptorjev NK1 v tej študiji je v dobri korelaciji s plazemskimi koncentracijami aprepitanta.
Although a 32 mg intravenous dose of ondansetron was used in clinical trials, this is no longer the recommended dose. 
Čeprav se je v kliničnih preskušanjih uporabljal 32 mg intravenski odmerek ondansetrona, to ni več priporočeni odmerek.
If you are pregnant or breast-feeding, may be pregnant or are planning to have a baby, ask your doctor for advice before receiving this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden boste prejeli to zdravilo.
For information regarding birth control, see ‘Other medicines and IVEMEND'. 
Za podatke glede kontracepcije glejte "Druga zdravila in zdravilo IVEMEND".
IVEMEND works by blocking signals to that area, thereby reducing nausea and vomiting. 
Zdravilo IVEMEND deluje tako, da blokira signale v to področje, s čimer zmanjšuje navzeo in bruhanje.
Gently invert the bag 2-3 times (see ‘How to use IVEMEND'). 
Vrečko 2 do 3 krat nežno obrnite (glejte "Kako uporabljati zdravilo IVEMEND").
If signs or symptoms of local irritation occur, the injection or infusion should be terminated and restarted in another vein. 
Če se pojavijo znaki ali simptomi lokalnega draženja, je treba injiciranje ali infundiranje prekiniti in zdravilo aplicirati v drugo veno.
Efficacy was based on evaluation of the following composite measures: complete response in both the overall and delayed phases and no vomiting in the overall phase. 
Učinkovitost zdravljenja je temeljila na oceni naslednjih sestavljenih meril: popoln odziv v celotni in zapozneli fazi in brez bruhanja v celotni fazi.
Do not give IVEMEND to children under 6 months of age or who weigh less than 6 kg, because it has not been studied in this population. 
Zdravila IVEMEND ne dajajte otrokom, mlajšim od 6 mesecev ali s telesno maso manj kot 6 kg, ker pri tej populaciji zdravilo ni bilo raziskano.
EU/1/07/437/003 1 x 1 vial EU/1/07/437/004 1 x 10 vials 
EU/1/07/437/003 1 x 1 viala EU/1/07/437/004 1 x 10 vial
Highly Emetogenic Chemotherapy (HEC) 
Zelo emetogena kemoterapija (HEC)
The contribution of fosaprepitant to the overall antiemetic effect has not fully been characterised, but a transient contribution during the initial phase cannot be ruled out. 
Prispevek fosaprepitanta k skupnemu antiemetičnemu delovanju ni povsem pojasnjen, vendar pa prehodnega učinka med uvodno fazo ni možno izključiti.
Pharmacotherapeutic group: Antiemetics and antinauseants, ATC code: A04AD12. 
Farmakoterapevtska skupina: Antiemetiki in zdravila proti slabosti, oznaka ATC: A04AD12.
Therefore, the recommendations for use of IVEMEND with other medicinal products in paediatric patients are based upon adult data from fosaprepitant and aprepitant studies. 
Zato priporočila za uporabo zdravila IVEMEND z drugimi zdravili pri pediatričnih bolnikih temeljijo na podatkih iz študij fosaprepitanta in aprepitanta pri odraslih.
It belongs to a group of medicines called "neurokinin 1 (NK1) receptor antagonists". 
Spada v skupino zdravil, imenovanih "antagonisti receptorjev za nevrokinin 1 (NK1)".
The potential effects on reproduction of alterations in neurokinin regulation are unknown. 
Možni učinki zaradi sprememb regulacije nevrokininov na sposobnost razmnoževanja niso znani.
Aprepitant is not excreted unchanged in urine. 
Aprepitant se ne izloča z urinom v nespremenjeni obliki.
P-Value 
p-vrednost
These hypersensitivity reactions have generally responded to discontinuation of the infusion and administration of appropriate therapy. 
Te preobčutljivostne reakcije so se običajno odzvale na prekinitev infuzije in ustrezno zdravljenje.
The estimated time to first emesis is depicted by the Kaplan-Meier plot in Figure 1. 
Ocenjeni čas do prvega bruhanja prikazuje Kaplan-Meierjeva krivulja na Sliki 1.
Therefore, there is no evidence of interaction with the use of IVEMEND 150 mg and 5-HT3 antagonists. 
Zato ni dokazov o medsebojnem delovanju pri uporabi zdravila IVEMEND 150 mg in antagonistov 5-HT3.
Other medicines and IVEMEND 
Druga zdravila in zdravilo IVEMEND
1-Day Regimen of Fosaprepitant in Adults 
1-dnevna shema fosaprepitanta pri odraslih
It is not known whether IVEMEND is excreted in human milk; therefore, breast-feeding is not recommended during treatment with this medicine. 
Ni znano, ali se zdravilo IVEMEND izloča v materino mleko, zato med zdravljenjem s tem zdravilom dojenje ni priporočljivo.
The efficacy of fosaprepitant was evaluated based on the primary and secondary endpoints listed in Table 8 and was shown to be superior to the control regimen with regard to complete response in the delayed and overall phases. 
Učinkovitost fosaprepitanta je bila ocenjena na osnovi primarnih in sekundarnih opazovanih dogodkov, navedenih v preglednici 8, in se je izkazala za boljšo od kontrolne sheme zdravljenja glede na popoln odziv v zapozneli in celotni fazi.
It is not known whether aprepitant is excreted in human milk. 
Ni znano, ali se aprepitant izloča v materino mleko.
For additional information on the co-administration with corticosteroids, see section 4.5. 
Za dodatne podatke o sočasni uporabi s kortikosteroidi glejte poglavje 4.5.
Aprepitant is highly protein bound, with a mean of 97 %. 
Aprepitant se močno veže na beljakovine, povprečno 97 %.